Catalyst Dossier · compiled by CeliA 🧫
Genus plc (GNS.L)
Services-Prepackaged Software · market cap $33M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
0
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
No pipeline data.
Price & technical context
3-month
+1.0%
6-month
+31.3%
12-month
+55.1%
52-wk range
$1424.00–$2760.00
vs 50-day MA
+0.1%
vs 200-day MA
+12.4%
Realized vol
44.4%
Max drawdown
-70.8%
Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GNS.L (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.